Dr. Chen Likun is a PhD, advisor of master’s degree student, associate professor of Medical Oncology in Sun Yat-sen University Cancer Center. She is a Youth Committee member of CSCO, Vice Team Leader of Youth Committee in Guangdong Anticancer Association specialized committee, member of Sun Yat-sen University Lung Cancer Center, member of specialized oncology committee of Guangdong Heath Management Association, member of specialized esophagus cancer committee in Guangdong Anticancer Association and Youth Committee member of branch association in oncology of Guangdong Medical Association, and member of ASCO.

In 2008, she won the award of “Ceclor Best Chinese Doctors”. Graduated from former Sun Yat-sen University of Medical Sciences, majored in clinical medicine, she then obtained a master’s degree in Sun Yat-sen University, majored in oncology and she’s been working in Medical Oncology in Sun Yat-sen University oncology center.

In 2006, she received a doctoral degree in oncology in Sun Yat-sen University, researching on the direction of medical treatment of lung cancer and nasopharynx cancer. She has an in-depth research on lung cancer treatment, especially in the complex treatment of brain metastasis for many years, including permeability research of chemotherapeutics brain metastasis BBB, research of combination therapy of chemotherapy, targeted therapy and brain radiotherapy, and research of individualized treatment of lung cancer with brain metastasis. She has achieved excellent research results in some related areas. She also has accumulated experience in the individualized treatment and sequential therapy for advanced lung cancer. She launched several researches about the lung cancer individualized targeted treatment and resistance mechanisms. She led and took part in many oncology researches at provincial and national levels, and projects about clinical research of new drugs in the national and international level. She also has publicized over 40 related papers in journals at home and abroad.

Medical treatment of lung cancer and nasopharyngeal carcinoma

09/2003-06/2006 Ph.D at the Department of Medical Oncology, Sun Yat-sen University Cancer Center; Ph. D Degree;

09/1996-06/1999 Postgraduate at the Department of Medical Oncology, Sun Yat-sen University Cancer Center, Master Degree;

09/1991-06/1996 Sun Yat-sen University of Medical Sciences (Now Known as Medical College of Sun Yat-Sen University), studying in Institute of Clinical Medicine and awarded Bachelor of clinical medicine, Bachelor Degree.

Xiao-xiao Dinglin, Yan Huang, Li-kun Chen (corresponding author). Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol. J Neurooncol 2013, 112:461-466 2. Li-kun Chen, He Huang, Hai Liao et al. Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: a phase II study. Med Oncol 2012, 29:1687–1692 3. Li-Kun Chen, Ying Liang, Qun-Ying Yang, et al. Triplet Platinum-based Combination Sequential Chemotherapy Improves Survival Outcome and Quality of Life of Advanced Non-small Cell Lung Cancer Patients. Asian Pac J Cancer Prev.2012,13(5):1863-1867 4. Yin-duo Zeng, Li Zhang, Li-kun Chen (corresponding author). Gefitinib Alone or with Concomitant Whole Brain Radiotherapy for Patients with Brain Metastasis from Non-small-cell Lung Cancer: A Retrospective Study. Asian Pac J Cancer Prev. 2012, 13(3):909-914 5. Li-kun Chen, You-jian He, He Huang, et al. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol. 2008, 25(2):161-171 6. Li-kun Chen, Guang-chuan XU, Zhong-zhen GUAN, et al. Nadaplatin or cisplatin combined with paclitaxol in treatment for non-small cell lung cancer: a randomized controlled study. Chinese Journal of Oncology, 2007,29(6):437-440 7. Li-kun Chen, Qun-ying Yang, Ying Ling, et al. Brain Radiotherapy Combined with Sequential Chemotherapy in Non-Small-Cell Lung Cancer Patients with Brain Metastases. Chinese Journal of Lung Cancer. 2009,12(8):896-900 8. Wei-dong Wei, Jian-hua Fu, Li-kun Chen (corresponding author) Establishment and evaluation of the survival and prognostic model for non-small cell lung cancer with complete resection. Chinese Journal of Oncology, 2008, 30(9):672-675 9. Li-kun Chen, You-jian He, Qun-ying Yang, et al. HER and COX-2 and NF-κB expressions in non-small cell lung cancer and correlation with survival. Chinese Journal of Cancer Prevention and Treatment 2007,14(5):366-369 10. Li-kun Chen, You-jian He, He Huang, et al. Toxicity of selective COX-2 inhibitor celecoxib on non-small cell lung cancer cell lines and the molecular mechanism in vitro. Chinese Journal of Cancer Prevention and Treatment .2007,14(12):901-904 11. Li-kun Chen, Guang-Chuan Xu, Guo-Zhen Liu, et al. Whole Brain Radiotherapy Combined with COAPC Regimen in Patients with Non-Small Cell Lung Cancer. Chinese Journal of Cancer. 2003, 22(4):407-410 12. Li-kun Chen, Guo-Zhen Liu, Guang-Chuan Xu. Brain Irradiation Enhances Permeability of cis-Diamminedichloroplatinum into Blood-Brain Barrier. Chinese Journal of Cancer. 2001,20(3):291-293 13. Li-kun Chen, Guang-chuan XU, Ying Ling, et al. Intrapericardial Infusion of Etoposide and Cisplatin in Treating Malignant Pericardial Effusion of Non-small Cell Lung Cancer. Chinese Journal of Cancer. 2006,25(4):505-508 14. Wei-dong Wei, Zhe-sheng Weng, Li-kun Chen (corresponding author). Multivariate Survival Analysis of 899 Patients with Non-small Cell Lung Cancer after Complete Resection. Chinese Journal of Cancer. 2007,26(11):1231-1236 15. Wei-dong Wei, Lan-jun Zhang, Li-kun Chen (corresponding author).The prognosis of completed resectable ⅢA non-small cell lung cancer and the suggestion of the treatment strategy. China Oncology. 2008,18(3):215-218

Updated by International Office, Sun Yat-sen University Cancer Center